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Background: Bleeding severity, anatomic location, tissue characteristics, and visibility are common challenges
encountered while managing intraoperative bleeding, and conventional hemostatic measures (suture, ligature,
and cautery) may sometimes be ineffective or impractical. While topical absorbable hemostats (TAH) are useful
hemostatic adjuvants, each TAH has associated disadvantages.
Methods: We evaluated the safety and hemostatic efficacy of a new advanced biologic combination
product―fibrin pad―to potentially address some gaps associated with TAHs. Fibrin pad was assessed as adjunctive
hemostat in open partial nephrectomy in single-center, open-label, Phase I study (N = 10), and as primary hemostat
in multicenter, single-blind, randomized, standard-of-care (SOC)-controlled Phase I/II study (N = 7) in Israel. It was
used to control mild-to-moderate bleeding in Phase I and also spurting arterial bleeding in Phase I/II study. Phase I
study assessed safety and Phase I/II study, proportion of successes at 10 min following randomization, analyzed by
Fisher exact tests at 5% significance level.
Results: Phase I (N = 10): All patients completed the study. Hemostasis was achieved within 3–4 min
(average = 3.1 min) of a single application in all patients. Fibrin pad was found to be safe for human use, with
no product-related adverse events reported. Phase I/II (N = 7): Hemostatic success at 10 min (primary endpoint)
was achieved in 3/4 patients treated with fibrin pad versus 0/3 patients treated with SOC. No clinically significant
change in laboratory or coagulation parameters was recorded, except a case of post-procedural hemorrhage
with fibrin pad, which was considered serious and related to the fibrin pad treatment, and required re-operation.
Although Data Safety Monitoring Board authorized trial continuation, the sponsor decided against proceeding
toward an indication for primary treatment of severe arterial hemorrhage as a replacement for sutures. The study
was suspended after 7/30 planned subjects were enrolled.
Conclusions: The first-in-man trial of fibrin pad demonstrated its safety and efficacy as an adjunctive hemostatic
technique for mild-to-moderate bleeding in partial nephrectomy. The study also suggested that the product
should not replace sutures or meticulous surgical techniques for the treatment of severe arterial hemorrhage.
Trial registration: Phase I/II trial, NCT00598130
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Nephron-sparing surgery (NSS) is currently a preferable
treatment for most patients with organ-confined renal
cancer. Compared to radical nephrectomy, NSS provides
excellent cancer control while providing renal function
preservation and in some patients, significantly better
survival [1,2]. There is increasing evidence of an associ-
ation between postoperative renal function and non-
cancer mortality, mainly due to cardiovascular events
[3,4]. The frequent use of NSS in small renal cell cancer
is attributed to the increasing incidental diagnosis of
renal tumors in patients undergoing abdominal ultra-
sound or computed tomography (CT) for various indica-
tions [5]. NSS is not yet completely accepted by
urologists, primarily because of difficulty in controlling
bleeding and the consequent hemodynamic instability
[6,7]. Hemostasis can be achieved by conventional surgi-
cal techniques such as suture ligature, cautery, and
argon beam coagulation. However, these techniques
are sometimes time consuming and may prove ineffect-
ive for persistent, extensive bleeding. More recently,
adjunctive hemostatic techniques using topical absorb-
able hemostats, e.g., oxidized regenerated cellulose, gel-
atin, or collagen and liquid fibrin sealants, have been
employed to decrease intraoperative renal ischemic time,
provide rapid hemostasis, and when surgical fields are
difficult to visualize [6,8-11]. Liquid sealants serve as
effective hemostatic adjuncts but may have limited use
in high-volume or high-pressure bleeding [12].
Fibrin pad (OMRIX Biopharmaceuticals Ltd., Israel;
Ethicon Inc., USA) was designed with the intention to
potentially overcome the limitations of other adjunctive
hemostatic products. It is a sterile, bio-absorbable com-
bination product of a coating of lyophilized biologically
active, human thrombin and fibrinogen. A pre-clinical
study in a swine partial nephrectomy model demon-
strated that direct application of fibrin pad was effective
in achieving hemostasis in every animal, with no fibrin
pad-related adverse reactions [13].
Here, we report the first-in-man use of a newly devel-
oped fibrin pad tested as an adjunct to conventional
hemostatic techniques, and as a primary/only method of
hemostasis during NSS in 2 early phase clinical studies.Methods
Both studies were conducted in Israel in accordance
with the requirements for conduct of clinical studies
(Ministry of Health, Good Clinical Practice Standard),
ICH Harmonised Tripartite Guideline for Good Clinical
Practice (2000), and the Declaration of Helsinki (1996).
The protocols for the studies were approved by Beilin-
son Hospital, Rabin Medical Center (Petah Tikva) and
Bnai Zion Medical Center (Haifa) ethics committees.All patients provided written informed consent before
study participation.
Fibrin pad
Fibrin pad is a sterile, bio-absorbable combination product
composed of lyophilized human plasma-derived fibrino-
gen (4.7-12.4 mg/cm2) and thrombin (15-45 IU/cm2),
which is similar to EVICELW Fibrin Sealant [Human]
[14,15] coated on a flexible matrix that consists of a woven
mesh of oxidized, regenerated cellulose [16] (similar to
SURGICELW Absorbable Hemostats and GYNECARE
INTERCEEDW Absorbable Adhesion Barrier) of plant ori-
gin, with polyglactin 910 (similar to VICRYL™ suture and
mesh products) filaments [13] (Figure 1A and 1B) func-
tioning as a mechanical barrier. Fibrin pad was supplied in
10 × 10 cm2 units and was to be cut to fit the wound site
with a margin of 1-2 cm beyond the wound. A dose
equivalent to 1 unit could be left in the body. In
Figure 1C, we show the application site of fibrin pad dur-
ing a porcine partial nephrectomy procedure conducted
in a preclinical laboratory setting.
Phase I study design
This single-center, open-label, prospective, non-rando-
mized, non-controlled study assessed the safety of fibrin
pad as an adjunct to conventional hemostatic procedures
in patients undergoing NSS. The study included patients
aged 18–75 years undergoing elective NSS for renal
tumors ≤4 cm in diameter. Patients having only 1 func-
tional kidney, undergoing additional surgical interven-
tions, or requiring cooling of the kidney; known
coagulopathy, abnormal prothrombin time, or inter-
national normalized ratio > 1.3; known intolerance to
blood products or other product components; or who
had recently received anticoagulants or anti-aggregates
were excluded.
Surgery was performed according to the standard
of care (SOC). Following segmental resection of the
renal tissue, when conventional hemostatic measures
were exhausted, fibrin pad was applied to the target
bleeding site (TBS) followed by manual pressure for
3 min; bleeding status was evaluated for 10 min since
application to assess the time required to achieve
hemostasis (Figure 2).
CBC, coagulation parameters, volume and type of
blood products transfused, and drainage fluid volume
(if applicable) were recorded. Follow-up visits occurred
2, 4, and 8 weeks post-surgery. Adverse events (AEs),
including bleeding-related complications, were moni-
tored throughout the study.
The primary endpoint was evaluation of safety based
on AE incidence and clinically abnormal laboratory and
coagulation parameters. Secondary endpoints included
time to hemostasis (TTH), time to total hemostasis
Figure 1 Scanning electron micrograph (SEM) image of fibrin pad. A) Top-view of fibrin pad, B) Cross section of bioactive matrix with
human fibrinogen and human thrombin powders retained by polyglactin 910 fibers, and C) Image of the product application site during porcine
partial nephrectomy.
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and surgeon’s evaluation of fibrin pad use. All statistical
analyses were performed using SAS version 9.1 (SAS In-
stitute, Cary, NC, USA).
Phase I/II study design
This was a prospective, multicenter, randomized, single-
blind, SOC-controlled study, which planned to recruit
30 subjects in 2 cohorts. The first cohort of 10 eligible
subjects was to be randomized in a 1:1 ratio to the fibrin
pad or SOC (electrosurgery, suture, absorbable hemostat,
and SURGICELW) group. Inclusion/exclusion criteria
were similar to those of the Phase I study, except that
the patients were 18–65 years old and were excluded if
the intraoperative blood collection by suction exceeded
500 mL (excluding irrigation liquids), sustained systolic
pressure was <80 mmHg, sustained heart rate was ≥130
beats per minute, or sustained oxygen saturation (SaO2)
was <90%. Screening criteria and baseline assessments
performed 24 h prior to the procedure were similar to
those of the Phase I study.
Randomization occurred once all intraoperative inclu-
sion criteria were met, and an appropriate TBS was iden-
tified following tumor excision. Treatment allocation
happened through an interactive voice response system.
Fibrin pad was applied to the TBS after removal of
excess blood or fluids, and hemostasis was assessed for10 min followed by a 6-min observation period (Figure 2).
In subjects randomized to the control arm, bleeding was
controlled by conventional surgical techniques and
hemostasis was assessed at similar time points as in the
fibrin pad group. In cases where vascular occlusion was
used, fibrin pad was applied simultaneously with the
opening of the clamp. Arterial clamping was employed
in Phase I study but not during active hemostat applica-
tion in Phase II. Intraoperative measurements and evalu-
ation of AEs were similar to those of the Phase I study.
Follow-up visits occurred at 2 weeks and 1 month.
The primary efficacy endpoint was the proportion of
successes at 10 min following randomization (defined as
complete hemostasis within 10 min and no further
bleeding during the subsequent 6-min observation
period). Secondary efficacy endpoints included propor-
tion of successes at 5 min following randomization,
laboratory assessments, safety, and parameters similar to
the secondary endpoints of the Phase I study.
The 2 treatment groups were compared for the pro-
portion of successes at 10 min and 5 min using Fisher
exact tests at a 5% significance level. For continuous
variables such as TTH, the 2 treatment groups were
compared using an analysis of variance (ANOVA) with
study center as a factor. For non-parametric tests, the
Wilcoxon rank-sum procedure with a continuity correc-
tion was used.
Figure 2 Time-table for assessment of hemostasis. Time points were recorded from start of kidney resection to the observation period for
both the studies. Time to hemostasis (TTH) and total time for hemostasis (TTTH) were calculated from these time points. *If complete hemostasis
was not achieved at 3 min, up to 2 additional applications were permitted within the 10-min evaluation period, starting immediately after the 1st
application, with the total fibrin pad used not exceeding a 10 x 10 cm2 unit. If hemostasis was not achieved during the 10-min evaluation period
with 3 applications of fibrin pad, the patient was recorded as treatment failure and further hemostatic measures based on physician preference
were employed.
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Phase I study
All 10 patients (mean age [SD], 64.5 [8.87] years) en-
rolled between December 2006 to August 2007 com-
pleted the study (Figure 3). Table 1 shows their
demographic data. Each patient received a single appli-
cation of fibrin pad; the mean estimated pad size used
was 30.5 cm2 (range, 9–64 cm2). A total of 19
treatment-emergent AEs were reported, with 9 of 10
patients experiencing at least 1 AE (Table 2A). There
were no deaths, serious adverse events (SAEs), or
treatment-related AEs. All treatment-emergent AEs were
rated as mild, except for 1 case of hypokalemia that was
moderate in intensity. Deviations in coagulation and
hematology parameters were transient, not clinically sig-
nificant, and expected due to the nature of the proced-
ure. Figure 4 shows the decrease in hemoglobin (Hb)and hematocrit (Hct) levels from baseline to 12 h post-
surgery. The TTH was 3 min in 9 of 10 patients (90%)
and 4 min in 1 patient. TTTH was 5–10 min in the
10 patients. No treatment failure or re-bleeding was
reported, and no patient required further surgery during
the 8-week follow-up period. The Ease of Use Question-
naire, completed by the 2 surgeons who performed the
surgery, rated the product as relatively easy to use and
assessed the product as able to achieve hemostasis
rapidly and safely.
Phase II study
The study population was evenly distributed between
the fibrin pad (n = 4) and SOC (n = 3) groups, with the
mean (SD) age of the subjects being 57.3 (10.00) years.
All 7 subjects completed the study between May–October
2008 (Figure 3). Table 1 shows the demographic data.
Table 2 Summary of adverse events
(A) Phase I study
Figure 3 Patient disposition of Phase I (Panel A) and Phase II (Panel B) studies.
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ping rules owing to an event of post-procedural hemor-
rhage from the TBS. This event was assessed by the study
data and safety monitoring board (DSMB), who recom-
mended study continuation. However, the sponsor made
the decision to not pursue the use of fibrin pad as the pri-
mary and sole treatment of severe arterial hemorrhage
that would require mechanical ligation.N = 10
Any AE, n (%) 9 (90.0)
SAE, n (%) 0 (0.0)
AEs related to investigational
product, n (%)
0 (0.0)
Most common AEs, n (%)
Nausea 2 (20.0)
Pyrexia 6 (60.0)Primary efficacy endpoint
Hemostatic success at 10 min was achieved in 3 of 4
patients (75%) in the fibrin pad group versus none of the
3 patients (0%) in the SOC group. However, this result
was not statistically significant given the small number
of observations.Table 1 Demographics and baseline characteristics






care N = 3
Age (years), mean (SD) 64.5 (8.87) 56.0 (7.87) 59.0 (14.11)
Weight (kg), mean (SD) 75.1 (10.41) 84.3 (14.15) 78.3 (18.15)
Height (cm),* mean (SD) 164.7 (10.95) 166.3 (11.44) 170.7 (8.08)
Gender, n (%)
Male 8 (80) 3 (75.0) 2 (66.7)
Female 2 (20) 1 (25.0) 1 (33.3)
Race, n (%)
Caucasian 10 (100) 4 (100) 3 (100)
* n = 7.Secondary efficacy endpoints
Hemostatic success at 5 min was not achieved in any pa-
tient in either group. The median TTH and TTTH were
shorter in the fibrin pad group than in the SOC group,Procedural site reaction 2 (20.0)




care (N = 3)
Total number of AEs 2 2
Incidence of AEs, n (%) 1 (25.0) 1 (33.3)
Incidence of SAEs, n (%) 1 (25.0) 0 (0.0)
AEs related to investigational
product, n (%)
Post-procedural hemorrhage 1 (25.0) 0 (0.0)
Most common AEs, n (%)
Epididymitis 1 (25.0) 0 (0.0)
Atelectasis 0 (0.0) 1 (33.3)
Postoperative wound infection 0 (0.0) 1 (33.3)
AE, adverse event; SAE, serious adverse event.
Figure 4 Changes in hemoglobin and hematocrit levels from
baseline to 12 h post-surgery in the Phase I open-label study.
There was a mean drop of 0.86 g/dL in the hemoglobin level and
2.3% in the hematocrit level over this period.
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(Table 3). All subjects in the fibrin pad group required
2 applications because hemostasis was not achieved
in 3 patients within 3 min of application and there
was an instance of re-bleeding in 1 patient during the
6-min observation period. All 3 patients in the SOC
group were listed as treatment failures. The decrease in
Hb and Hct levels from baseline to the day of discharge
was lower in the fibrin pad group than in the SOC
group. Changes in the hematology and coagulation la-




Time to hemostasis (min)
Mean (SD) 3.1 (0.31)
Median (range) 3 (3–4)
Total time to hemostasis (min)
Mean (SD) 6.2 (1.54)
Median (range) 6 (5–10)
*Fibrin pad was used as an adjunct in Phase I and as the primary treatment in Phas
†Wilcoxon 2-sample test.significant, except for those in the patient who experi-
enced post-procedural hemorrhage.
Safety
A total of 4 AEs were reported in 2 subjects in each
group during the study period (Table 2). Three events
were non-serious, mild in intensity, and considered
unrelated to the study treatment, whereas 1 event, an
episode of post-procedural hemorrhage in a subject in
the fibrin pad group, was considered serious, severe in
intensity, and related to the study treatment. Bleeding
was observed in the drain 2 h after surgery, and the
patient was hemodynamically instable. This episode
required the subject to be re-operated, and the source of
bleeding was the resection area beneath the fibrin pad.
The fibrin pad was removed, and hemostasis was
achieved using a standard surgical technique. This
patient was administered a total of 10 units of blood in
the postoperative period and was discharged from the
hospital without sequelae.Discussion
NSS is performed by many urologists endoscopically,
and it has emerged as an alternative to radical nephrec-
tomy for removal of small (≤4 cm diameter) as well as
larger renal masses, since cancer-specific survival out-
comes are similar for both approaches, even in young
patients [17,18]. However, achieving rapid and effective
hemostasis in NSS can be challenging. Fibrin pad was
designed to provide surgeons an alternative adjunct to
hemostatic techniques for achieving rapid control of
mild, moderate, and severe bleeding in a variety of tissue
types. In the current Phase I study, complete hemostasis
was achieved in all patients within 3–4 min of a single
application of the fibrin pad, without the occurrence of
re-bleeding. This has immense clinical significance as it
has been reported that each additional minute of warm
ischemia following partial nephrectomy is associated




care N = 3
P value*
15.0 (13.41) 21.0 (7.94)
8.4 (8–35) 18.0 (15–30) 0.41
16.0 (13.00) 21.3 (8.50)
9.0 (9–36) 18.0 (15–31) 0.41
e I/II.
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rate of <15 mL/min per 1.73 m2 in the postoperative
period, and a 6% increase in the risk of new-onset stage
IV chronic kidney disease during follow-up [19]. Tech-
nologies similar to the fibrin pad have been demon-
strated to be effective in sealing air leakage in the lung
[20] and for achieving hemostasis in the kidney [14] and
liver [21]. TachoSil™, an equine collagen patch coated
on one side with human fibrinogen and thrombin, has
been used in clinical trials; however, animal collagen
could be a concern in allergic patients [22-24].
In the Phase II study, where fibrin pad was used as the
primary and sole hemostat, the upper limit of product
performance was tested by assessing its efficacy in con-
trolling severe arterial bleeding from the highly vascular
renal parenchyma. Although hemostasis was achieved,
all patients in the fibrin pad group required reapplica-
tion of the product. This may be attributed to the learn-
ing curve of surgeons and also to the fact that the fibrin
pad requires direct and complete product-to-tissue sur-
face apposition with persistent manual compression to
activate the biologic components and develop tissue ad-
herence, which may have been challenging given the
irregular wound geometry. Intraoperative treatment fail-
ure was observed in all 3 patients in the SOC group,
where vascular clamping was used. Since no vascular
clamping was required in the fibrin pad group, the possi-
bility of ischemia is minimal.
Fibrin pad builds on the EVICELW liquid fibrin sealant
technology consisting of virus-inactivated, human
plasma-derived thrombin and fibrinogen [15,25]. The 2
components are mixed during application and upon
combination, mimic the final step in the blood coagula-
tion pathway to form a stable clot [11,26]. Furthermore,
the biological components of the fibrin pad are free of
tranexamic acid and aprotinin, which have been asso-
ciated with neurological AEs and hypersensitivity reac-
tions, respectively [27,28]. The fibrin sealant may be
rendered ineffective if it is removed from the TBS due
to adhesive or cohesive failure, particularly in severe
bleeding [12,24,29,30]. In a prospective, randomized
controlled trial that compared the safety and hemostatic
effectiveness of a fibrin sealant (EVICELW; 75 patients)
to manual compression (72 patients) during vascular
surgery, Chalmers et al. demonstrated that a higher per-
centage of patients who received the fibrin sealant
achieved hemostasis at 4 min as compared to those who
received manual compression (85% vs. 39%; P < 0.001)
[15], showing that biological components present in the
fibrin pad are effective in achieving hemostasis.
While fibrin sealants have proven efficacy in intrao-
perative hemostasis, Cornum et al. evaluated the ability
of an absorbable fibrin adhesive bandage (AFAB), a
prototype product comprising lyophilized fibrinogen andthrombin on a VICRYL mesh backing, to seal the col-
lecting system and control bleeding after partial neph-
rectomy in growing pigs [8]. Compared to conventional
management, the use of AFAB resulted in significantly
less bleeding (357 mL vs. 13 mL with AFAB; P < 0.001),
shorter operative and ischemic times, a stable clot, and
healing that is at least as successful as conventional
treatments. A case series on the use of fibrin sealant
applied over an absorbable hemostat, SURGICELW after
argon beam coagulation in 15 patients undergoing lap-
aroscopic wedge resection of small renal lesions reported
that hemostasis was achieved in all patients, and no
blood transfusion was required [16]. These studies
demonstrated that a combination of biological compo-
nents on a bio-absorbable pad, as used in the current
study, was effective for hemostasis.
Furthermore, a pre-clinical study in a severe renal
bleeding swine model demonstrated that fibrin pad was
as effective as conventional therapy in achieving durable
hemostasis, and no case of re-bleeding or systemic/
local adverse response was observed during the 8-week
follow-up period [13].
Conclusions
This paper reports the first-in-man use of fibrin pad, a
potential life-saving technology, as an adjunctive
hemostat. All patients in the Phase I study demonstrated
complete and rapid hemostasis with the fibrin pad with-
out any safety concerns. The Phase II study tested the
upper limit of product performance and suggested that
the product should be used as an adjunct to hemostats
and should not replace suture ligation for severe arterial
hemorrhage. Subsequent clinical trials will be needed to
determine the product’s clinical utility and safety profile
for varying degrees of bleeding and across a spectrum of
tissue types and surgical situations.
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